AirSculpt Technologies operates a practice-management company built around a single patented procedure, a minimally invasive form of liposuction it markets as the AirSculpt method, across 31 centers in 20 U.S. states and Canada. For the three months ended June 30, 2026 the company generated $42.9 million of revenue, a roughly 3% decline from the $44.0 million it reported in the year-ago quarter, as total cases slipped to 3,376 from 3,392 and revenue per case fell to $12,707 from $12,975. The quarter was a continuation of a multi-year contraction: fiscal 2025 revenue of $151.8 million was down 15.8% from $180.4 million in fiscal 2024, and the company itself discloses that it experienced revenue declines in both the 2024 and 2025 fiscal years. The deeper story is not the quarter's numbers but the structural force bearing down on the entire category. The company explicitly identifies the increased market acceptance and availability of obesity and weight-loss drugs, such as GLP-1 medications, as a direct competitive threat to demand for its surgical fat-reduction procedures, and management has responded with cost-cutting, advertising built around lower customer-acquisition costs, and a debt-reduction campaign.
The financial model remains cash-generative at the operating level even as the top line shrinks. Adjusted EBITDA was $4.9 million in the second quarter of 2026, an 11.5% margin, down from $5.8 million and a 13.3% margin a year earlier, and the first-half figure was $8.2 million at a 10.0% margin compared to $9.6 million at 11.5% in the first half of 2025. The company raised $19.6 million of net proceeds in the first half of 2026 through an at-the-market offering of 6.9 million shares, paid down $12.7 million of term-loan principal, and entered a Fourth Amendment to its credit agreement on August 7, 2026 that pushes the maturity to November 15, 2027 and secures mandatory debt payments. Cash and cash equivalents stood at $18.8 million as of June 30, 2026, up from $8.4 million at year-end 2025, while total borrowing under the credit facility had a carrying value of $43.6 million.
In our view the load-bearing question for the equity is whether the company can stabilize revenue and complete a refinancing of its secured term loan before a tightening series of deadlines under the amended credit facility, which requires a wholesale discharge of the obligations by October 31, 2026 and, failing that, the retention of investment banks to force a refinancing. The company is also selling equity into a depressed stock price, roughly $3.43 as of mid-August 2026 against a 52-week range of $1.51 to $12.00, which mechanically dilutes holders even as it funds debt reduction. The falsifiable clock consists of the third-quarter revenue and case trends, the next credit agreement event or refinancing announcement, and whether same-center revenue per case stabilizes above the current downward drift.